Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

Ahmet Emre Eşkazan1, Teoman Soysal2
1Diyarbakır Training and Research Hospital, Department of Hematology, Diyarbakır, Turkey
2İstanbul University Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey

Address for Correspondence: Teoman SOYSAL, M.D., İstanbul University Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey

To the Editor,

The most common mechanisms for resistance in patients with chronic myeloid leukemia (CML) receiving imatinib mesylate are BCR-ABL kinase domain (KD) mutations. The mutations are stratified according to in vitro 50% inhibitory concentration (IC50) values. The F317L KD mutation has been shown to induce a 9- to 13.5-fold increase of dasatinib IC50 with respect to wild-type BCR-ABL in cellular assays [1]. The pharmacokinetic data showed that F317L is predicted to be moderately sensitive to dasatinib [2]. Jabbour et al. [3] published data on a cohort of 20 CML patients with F317L mutation and evaluated the characteristics and outcomes of these patients with tyrosine-kinase inhibitor (TKI) therapy. Among these 20 patients, F317L was detected in 12 after imatinib failure and in 8 after dasatinib failure. In the post-imatinib failure group, 3 patients received dasatinib. The best achieved response was partial hematologic response in 1 and complete hematologic response (CHR) in 2. Müller et al. [4] also reported the results of analysis of original dasatinib phase 2/3 trial data according to pre-existing mutations. Of the 402 patients with baseline KD mutations, 14 had F317L mutations; 13 (93%), 2 (14%), and 1 (7%) achieved CHR, major cytogenetic response (MCyR), and complete cytogenetic response (CCyR), respectively. None of the patients achieved major molecular response (MMR).

Among our CML cohort, we identified KD mutations by the denaturing high performance liquid chromatography sequencing method as described before [5]. In the literature, it has been recently demonstrated by our group as well as by some others that there are CML patients with F317L mutation who achieved and maintained both CCyR and MMR with dasatinib after imatinib failure (Table 1) [6,7,8,9]. Dasatinib is known to have significant therapeutic activity against the Src kinases, and this is responsible for several of its “off-target effects”. Pulmonary toxicity [i.e. pleural effusion (PE)] following dasatinib use can be observed in CML patients [10]. Lymphocytosis in CML patients receiving dasatinib might have contributed to therapeutic efficacy, and Mustjoki et al. [11] showed a strong association between clonal T/NK cell expansion and lymphocytic PE under dasatinib therapy and prolonged stable responses in patients with advanced Ph-positive leukemias. Among the 4 CML cases described in the literature with F317L in which MMR was achieved with dasatinib, 3 had episodes of reversible dasatinib-induced PEs and modest lymphocytosis was seen in 1 (Table 1). These clinical and laboratory findings may be attributed to the good response in these patients.

In conclusion, evidence indicating the resistance of the F317L mutation to TKIs mainly comes from in vitro
Table 1: Characteristics of CML patients with F317L mutation with MMR under dasatinib published in the literature.

| Author, year     | Age in years/sex | CML stage at the start of imatinib | Best response to imatinib | Response duration to imatinib, months | Duration of imatinib treatment, months | KD mutations other than F317L | CML stage at imatinib failure | Dasatinib dose, mg/day | Duration of dasatinib treatment, months | Best response to dasatinib | Off-target effects of dasatinib | Follow-up after imatinib failure, months |
|------------------|------------------|-------------------------------------|---------------------------|---------------------------------------|----------------------------------------|----------------------------------|-----------------------------|-------------------------------|----------------------------------------|-------------------------|------------------------------------------|---------------------------------------------|
| Faber et al., 2010 [6] | 52/M             | L-CP                                | CCyR                      | 27                                    | 42                                     | E279K and H396R                  | CP                          | 140                           | 20                                     | CCyR and MMR                     | PE and lymphocytosis                             | 35                          |
| Oyekunle et al., 2011 [7] | 59/F             | L-CP                                | CHR and mCyR              | 25                                    | 31                                     | H396R                            | CP                          | 140                           | 54                                     | CCyR and MMR                     | PE                                      | 60                          |
| Eskazan et al., 2011 [8] | 45/F             | E-CP                                | CCyR and MMR              | 38                                    | 38                                     | none                             | CP                          | 100                           | 38                                     | CCyR and CMR                     | PE                                      | 38                          |
| Intermesoli et al., 2011 [9] | 40/M             | L-CP                                | CCyR                      | 36                                    | 54                                     | E255K                            | CP                          | 140                           | 34                                     | CCyR and CMR                     | none                                    | 66                          |

M= male, F= female, L-CP= late chronic phase, E-CP = early chronic phase, CP= chronic phase, CCyR= complete cytogenetic response, MMR= major molecular response, CMR= complete molecular response, mCyR= minor cytogenetic response, DAS= dasatinib, PE= pleural effusion.
studies. Since mutations are classified on the basis of their in vitro sensitivity to TKIs, the in vivo outcomes may not be in accordance with in vitro studies in every case. The presence of the F317L KD mutation may not uniformly predict poor outcomes in CML patients mainly on dasatinib. Outcomes may be related to a complex interplay of several factors possibly including the off-target effects of the TKI. It is important to carefully investigate and monitor individual patients, and although a switch to a TKI with better in vitro potency against a mutation may improve outcome, this strategy might not always be necessary, especially if the patient is in durable cytogenetic or molecular response.

Conflict of Interest

None of authors of this paper has any conflicts of interest, including specific financial interests, relationships, and/or affiliations, relevant to the subject matter or materials included in this manuscript.

References

1. O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505.

2. Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW. Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J Clin Oncol 2010;28:169-171.

3. Jabbour E, Kantarjian HM, Jones D, Reddy N, O’Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008;112:4839-4842.

4. Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944-4953.

5. Erbilgin Y, Çatal S, Eşkazan AE, Hatarnaz Ö, Sosyal T, Özbek U. ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method. Turk J Hematol 2011;28:97-102.

6. Faber E, Mouzikova R, Plachy R, Rozmanova S, Stastry M, Divoka M, Jarosova M, Indrak K, Dtvoky V. Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation. Leuk Res 2010;34:91-93.

7. Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib. Leuk Res 2011;35:118-120.

8. Eşkazan AE, Soysal T, Erbilgin Y, Ozbek U, Ferhanoglu B. Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients? Leuk Res 2011;35:145-146.

9. Intermesoli T, Castagnetti F, Soverini S, Bussini A, Spinelli O, Gnani A, Bassan R, Rosti G. Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib. Leuk Res 2012;36:10-11.

10. Eşkazan AE, Soysal T, Ongoren S, Gulturk E, Ferhanoglu B, Aydin Y. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica 2011;96:15.

11. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epllng-Burnette PK, Gulihat F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405.